

Antihyperuricemic Agents Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/AF2447566069EN.html>

Date: March 2022

Pages: 122

Price: US\$ 3,250.00 (Single User License)

ID: AF2447566069EN

Abstracts

Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.

This report contains market size and forecasts of Antihyperuricemic Agents in global, including the following market information:

Global Antihyperuricemic Agents Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Antihyperuricemic Agents Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Antihyperuricemic Agents companies in 2021 (%)

The global Antihyperuricemic Agents market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Inhibit Uric Acid Production Agents Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antihyperuricemic Agents include Takeda Pharmaceuticals, Hikma, Wockhardt, West Ward Pharmaceuticals, Rhea Pharmaceutical, Medinova, Odan Laboratories, TEIJIN and Casper Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihyperuricemic Agents manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antihyperuricemic Agents Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Antihyperuricemic Agents Market Segment Percentages, by Type, 2021 (%)

Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others

Global Antihyperuricemic Agents Market, by Distribution Channel, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Antihyperuricemic Agents Market Segment Percentages, by Distribution Channel, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Antihyperuricemic Agents Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Antihyperuricemic Agents Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antihyperuricemic Agents revenues in global market, 2017-2022
(Estimated), (\$ millions)

Key companies Antihyperuricemic Agents revenues share in global market, 2021 (%)

Key companies Antihyperuricemic Agents sales in global market, 2017-2022
(Estimated), (K Units)

Key companies Antihyperuricemic Agents sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Takeda Pharmaceuticals

Hikma

Wockhardt

West Ward Pharmaceuticals

Rhea Pharmaceutical

Medinova

Odan Laboratories

TEIJIN

Casper Pharma

Dr. Reddys Laboratories

Teva

Zydus Pharmaceuticals

Mylan

Sun Pharmaceutical

APOTEX

NorthStar Healthcare

Ipca Laboratories

Accord Healthcare

Gentec Pharmaceutical Group

Indoco Remedies

Lupin

Waterstone Pharmaceuticals

ALP Pharm

Jiangsu Hengrui Medicine

Jiangsu Wanbang Biopharmaceuticals

Hangzhou Zhuyangxin Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

KPC Pharmaceuticals

Tonghua Limin

Beijing Jialin Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Antihyperuricemic Agents Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Distribution Channel
- 1.3 Global Antihyperuricemic Agents Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTIHYPERURICEMIC AGENTS OVERALL MARKET SIZE

- 2.1 Global Antihyperuricemic Agents Market Size: 2021 VS 2028
- 2.2 Global Antihyperuricemic Agents Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Antihyperuricemic Agents Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Antihyperuricemic Agents Players in Global Market
- 3.2 Top Global Antihyperuricemic Agents Companies Ranked by Revenue
- 3.3 Global Antihyperuricemic Agents Revenue by Companies
- 3.4 Global Antihyperuricemic Agents Sales by Companies
- 3.5 Global Antihyperuricemic Agents Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Antihyperuricemic Agents Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Antihyperuricemic Agents Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Antihyperuricemic Agents Players in Global Market
 - 3.8.1 List of Global Tier 1 Antihyperuricemic Agents Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Antihyperuricemic Agents Companies

4 SIGHTS BY PRODUCT

- 4.1 Overview

- 4.1.1 By Type - Global Antihyperuricemic Agents Market Size Markets, 2021 & 2028
- 4.1.2 Inhibit Uric Acid Production Agents
- 4.1.3 Promote Uric Acid Excretion Agents
- 4.1.4 Others
- 4.2 By Type - Global Antihyperuricemic Agents Revenue & Forecasts
 - 4.2.1 By Type - Global Antihyperuricemic Agents Revenue, 2017-2022
 - 4.2.2 By Type - Global Antihyperuricemic Agents Revenue, 2023-2028
 - 4.2.3 By Type - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028
- 4.3 By Type - Global Antihyperuricemic Agents Sales & Forecasts
 - 4.3.1 By Type - Global Antihyperuricemic Agents Sales, 2017-2022
 - 4.3.2 By Type - Global Antihyperuricemic Agents Sales, 2023-2028
 - 4.3.3 By Type - Global Antihyperuricemic Agents Sales Market Share, 2017-2028
- 4.4 By Type - Global Antihyperuricemic Agents Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY DISTRIBUTION CHANNEL

5.1 Overview

- 5.1.1 By Distribution Channel - Global Antihyperuricemic Agents Market Size, 2021 & 2028
- 5.1.2 Hospital Pharmacies
- 5.1.3 Retail Pharmacies
- 5.1.4 Online Pharmacies

5.2 By Distribution Channel - Global Antihyperuricemic Agents Revenue & Forecasts

- 5.2.1 By Distribution Channel - Global Antihyperuricemic Agents Revenue, 2017-2022
- 5.2.2 By Distribution Channel - Global Antihyperuricemic Agents Revenue, 2023-2028
- 5.2.3 By Distribution Channel - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028

5.3 By Distribution Channel - Global Antihyperuricemic Agents Sales & Forecasts

- 5.3.1 By Distribution Channel - Global Antihyperuricemic Agents Sales, 2017-2022
- 5.3.2 By Distribution Channel - Global Antihyperuricemic Agents Sales, 2023-2028
- 5.3.3 By Distribution Channel - Global Antihyperuricemic Agents Sales Market Share, 2017-2028

5.4 By Distribution Channel - Global Antihyperuricemic Agents Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Antihyperuricemic Agents Market Size, 2021 & 2028

- 6.2 By Region - Global Antihyperuricemic Agents Revenue & Forecasts
 - 6.2.1 By Region - Global Antihyperuricemic Agents Revenue, 2017-2022
 - 6.2.2 By Region - Global Antihyperuricemic Agents Revenue, 2023-2028
 - 6.2.3 By Region - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028
- 6.3 By Region - Global Antihyperuricemic Agents Sales & Forecasts
 - 6.3.1 By Region - Global Antihyperuricemic Agents Sales, 2017-2022
 - 6.3.2 By Region - Global Antihyperuricemic Agents Sales, 2023-2028
 - 6.3.3 By Region - Global Antihyperuricemic Agents Sales Market Share, 2017-2028
- 6.4 North America
 - 6.4.1 By Country - North America Antihyperuricemic Agents Revenue, 2017-2028
 - 6.4.2 By Country - North America Antihyperuricemic Agents Sales, 2017-2028
 - 6.4.3 US Antihyperuricemic Agents Market Size, 2017-2028
 - 6.4.4 Canada Antihyperuricemic Agents Market Size, 2017-2028
 - 6.4.5 Mexico Antihyperuricemic Agents Market Size, 2017-2028
- 6.5 Europe
 - 6.5.1 By Country - Europe Antihyperuricemic Agents Revenue, 2017-2028
 - 6.5.2 By Country - Europe Antihyperuricemic Agents Sales, 2017-2028
 - 6.5.3 Germany Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.4 France Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.5 U.K. Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.6 Italy Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.7 Russia Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.8 Nordic Countries Antihyperuricemic Agents Market Size, 2017-2028
 - 6.5.9 Benelux Antihyperuricemic Agents Market Size, 2017-2028
- 6.6 Asia
 - 6.6.1 By Region - Asia Antihyperuricemic Agents Revenue, 2017-2028
 - 6.6.2 By Region - Asia Antihyperuricemic Agents Sales, 2017-2028
 - 6.6.3 China Antihyperuricemic Agents Market Size, 2017-2028
 - 6.6.4 Japan Antihyperuricemic Agents Market Size, 2017-2028
 - 6.6.5 South Korea Antihyperuricemic Agents Market Size, 2017-2028
 - 6.6.6 Southeast Asia Antihyperuricemic Agents Market Size, 2017-2028
 - 6.6.7 India Antihyperuricemic Agents Market Size, 2017-2028
- 6.7 South America
 - 6.7.1 By Country - South America Antihyperuricemic Agents Revenue, 2017-2028
 - 6.7.2 By Country - South America Antihyperuricemic Agents Sales, 2017-2028
 - 6.7.3 Brazil Antihyperuricemic Agents Market Size, 2017-2028
 - 6.7.4 Argentina Antihyperuricemic Agents Market Size, 2017-2028
- 6.8 Middle East & Africa
 - 6.8.1 By Country - Middle East & Africa Antihyperuricemic Agents Revenue,

2017-2028

- 6.8.2 By Country - Middle East & Africa Antihyperuricemic Agents Sales, 2017-2028
- 6.8.3 Turkey Antihyperuricemic Agents Market Size, 2017-2028
- 6.8.4 Israel Antihyperuricemic Agents Market Size, 2017-2028
- 6.8.5 Saudi Arabia Antihyperuricemic Agents Market Size, 2017-2028
- 6.8.6 UAE Antihyperuricemic Agents Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Takeda Pharmaceuticals

- 7.1.1 Takeda Pharmaceuticals Corporate Summary
- 7.1.2 Takeda Pharmaceuticals Business Overview
- 7.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Major Product Offerings
- 7.1.4 Takeda Pharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.1.5 Takeda Pharmaceuticals Key News

7.2 Hikma

- 7.2.1 Hikma Corporate Summary
- 7.2.2 Hikma Business Overview
- 7.2.3 Hikma Antihyperuricemic Agents Major Product Offerings
- 7.2.4 Hikma Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.2.5 Hikma Key News

7.3 Wockhardt

- 7.3.1 Wockhardt Corporate Summary
- 7.3.2 Wockhardt Business Overview
- 7.3.3 Wockhardt Antihyperuricemic Agents Major Product Offerings
- 7.3.4 Wockhardt Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.3.5 Wockhardt Key News

7.4 West Ward Pharmaceuticals

- 7.4.1 West Ward Pharmaceuticals Corporate Summary
- 7.4.2 West Ward Pharmaceuticals Business Overview
- 7.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Major Product Offerings
- 7.4.4 West Ward Pharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.4.5 West Ward Pharmaceuticals Key News

7.5 Rhea Pharmaceutical

- 7.5.1 Rhea Pharmaceutical Corporate Summary
- 7.5.2 Rhea Pharmaceutical Business Overview
- 7.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Major Product Offerings

7.5.4 Rhea Pharmaceutical Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.5.5 Rhea Pharmaceutical Key News

7.6 Medinova

7.6.1 Medinova Corporate Summary

7.6.2 Medinova Business Overview

7.6.3 Medinova Antihyperuricemic Agents Major Product Offerings

7.6.4 Medinova Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.6.5 Medinova Key News

7.7 Odan Laboratories

7.7.1 Odan Laboratories Corporate Summary

7.7.2 Odan Laboratories Business Overview

7.7.3 Odan Laboratories Antihyperuricemic Agents Major Product Offerings

7.7.4 Odan Laboratories Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.7.5 Odan Laboratories Key News

7.8 TEIJIN

7.8.1 TEIJIN Corporate Summary

7.8.2 TEIJIN Business Overview

7.8.3 TEIJIN Antihyperuricemic Agents Major Product Offerings

7.8.4 TEIJIN Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.8.5 TEIJIN Key News

7.9 Casper Pharma

7.9.1 Casper Pharma Corporate Summary

7.9.2 Casper Pharma Business Overview

7.9.3 Casper Pharma Antihyperuricemic Agents Major Product Offerings

7.9.4 Casper Pharma Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.9.5 Casper Pharma Key News

7.10 Dr. Reddys Laboratories

7.10.1 Dr. Reddys Laboratories Corporate Summary

7.10.2 Dr. Reddys Laboratories Business Overview

7.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Major Product Offerings

7.10.4 Dr. Reddys Laboratories Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.10.5 Dr. Reddys Laboratories Key News

7.11 Teva

7.11.1 Teva Corporate Summary

7.11.2 Teva Antihyperuricemic Agents Business Overview

- 7.11.3 Teva Antihyperuricemic Agents Major Product Offerings
- 7.11.4 Teva Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.11.5 Teva Key News
- 7.12 Zydus Pharmaceuticals
 - 7.12.1 Zydus Pharmaceuticals Corporate Summary
 - 7.12.2 Zydus Pharmaceuticals Antihyperuricemic Agents Business Overview
 - 7.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Major Product Offerings
 - 7.12.4 Zydus Pharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.12.5 Zydus Pharmaceuticals Key News
- 7.13 Mylan
 - 7.13.1 Mylan Corporate Summary
 - 7.13.2 Mylan Antihyperuricemic Agents Business Overview
 - 7.13.3 Mylan Antihyperuricemic Agents Major Product Offerings
 - 7.13.4 Mylan Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.13.5 Mylan Key News
- 7.14 Sun Pharmaceutical
 - 7.14.1 Sun Pharmaceutical Corporate Summary
 - 7.14.2 Sun Pharmaceutical Business Overview
 - 7.14.3 Sun Pharmaceutical Antihyperuricemic Agents Major Product Offerings
 - 7.14.4 Sun Pharmaceutical Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.14.5 Sun Pharmaceutical Key News
- 7.15 APOTEX
 - 7.15.1 APOTEX Corporate Summary
 - 7.15.2 APOTEX Business Overview
 - 7.15.3 APOTEX Antihyperuricemic Agents Major Product Offerings
 - 7.15.4 APOTEX Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.15.5 APOTEX Key News
- 7.16 NorthStar Healthcare
 - 7.16.1 NorthStar Healthcare Corporate Summary
 - 7.16.2 NorthStar Healthcare Business Overview
 - 7.16.3 NorthStar Healthcare Antihyperuricemic Agents Major Product Offerings
 - 7.16.4 NorthStar Healthcare Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.16.5 NorthStar Healthcare Key News
- 7.17 Ipca Laboratories
 - 7.17.1 Ipca Laboratories Corporate Summary
 - 7.17.2 Ipca Laboratories Business Overview

- 7.17.3 Ipca Laboratories Antihyperuricemic Agents Major Product Offerings
- 7.17.4 Ipca Laboratories Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.17.5 Ipca Laboratories Key News
- 7.18 Accord Healthcare
 - 7.18.1 Accord Healthcare Corporate Summary
 - 7.18.2 Accord Healthcare Business Overview
 - 7.18.3 Accord Healthcare Antihyperuricemic Agents Major Product Offerings
 - 7.18.4 Accord Healthcare Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.18.5 Accord Healthcare Key News
- 7.19 Gentec Pharmaceutical Group
 - 7.19.1 Gentec Pharmaceutical Group Corporate Summary
 - 7.19.2 Gentec Pharmaceutical Group Business Overview
 - 7.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Major Product Offerings
 - 7.19.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.19.5 Gentec Pharmaceutical Group Key News
- 7.20 Indoco Remedies
 - 7.20.1 Indoco Remedies Corporate Summary
 - 7.20.2 Indoco Remedies Business Overview
 - 7.20.3 Indoco Remedies Antihyperuricemic Agents Major Product Offerings
 - 7.20.4 Indoco Remedies Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.20.5 Indoco Remedies Key News
- 7.21 Lupin
 - 7.21.1 Lupin Corporate Summary
 - 7.21.2 Lupin Business Overview
 - 7.21.3 Lupin Antihyperuricemic Agents Major Product Offerings
 - 7.21.4 Lupin Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.21.5 Lupin Key News
- 7.22 Waterstone Pharmaceuticals
 - 7.22.1 Waterstone Pharmaceuticals Corporate Summary
 - 7.22.2 Waterstone Pharmaceuticals Business Overview
 - 7.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Major Product Offerings
 - 7.22.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.22.5 Waterstone Pharmaceuticals Key News

7.23 ALP Pharm

7.23.1 ALP Pharm Corporate Summary

7.23.2 ALP Pharm Business Overview

7.23.3 ALP Pharm Antihyperuricemic Agents Major Product Offerings

7.23.4 ALP Pharm Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.23.5 ALP Pharm Key News

7.24 Jiangsu Hengrui Medicine

7.24.1 Jiangsu Hengrui Medicine Corporate Summary

7.24.2 Jiangsu Hengrui Medicine Business Overview

7.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Major Product Offerings

7.24.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.24.5 Jiangsu Hengrui Medicine Key News

7.25 Jiangsu Wanbang Biopharmaceuticals

7.25.1 Jiangsu Wanbang Biopharmaceuticals Corporate Summary

7.25.2 Jiangsu Wanbang Biopharmaceuticals Business Overview

7.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Major Product Offerings

7.25.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.25.5 Jiangsu Wanbang Biopharmaceuticals Key News

7.26 Hangzhou Zhuyangxin Pharmaceutical

7.26.1 Hangzhou Zhuyangxin Pharmaceutical Corporate Summary

7.26.2 Hangzhou Zhuyangxin Pharmaceutical Business Overview

7.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Major Product Offerings

7.26.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.26.5 Hangzhou Zhuyangxin Pharmaceutical Key News

7.27 YiChang HEC ChangJiang Pharmaceutical

7.27.1 YiChang HEC ChangJiang Pharmaceutical Corporate Summary

7.27.2 YiChang HEC ChangJiang Pharmaceutical Business Overview

7.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Major Product Offerings

7.27.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)

7.27.5 YiChang HEC ChangJiang Pharmaceutical Key News

7.28 KPC Pharmaceuticals

- 7.28.1 KPC Pharmaceuticals Corporate Summary
- 7.28.2 KPC Pharmaceuticals Business Overview
- 7.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Major Product Offerings
- 7.28.4 KPC Pharmaceuticals Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
- 7.28.5 KPC Pharmaceuticals Key News
- 7.29 Tonghua Limin
 - 7.29.1 Tonghua Limin Corporate Summary
 - 7.29.2 Tonghua Limin Business Overview
 - 7.29.3 Tonghua Limin Antihyperuricemic Agents Major Product Offerings
 - 7.29.4 Tonghua Limin Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.29.5 Tonghua Limin Key News
- 7.30 Beijing Jialin Pharmaceutical
 - 7.30.1 Beijing Jialin Pharmaceutical Corporate Summary
 - 7.30.2 Beijing Jialin Pharmaceutical Business Overview
 - 7.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Major Product Offerings
 - 7.30.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales and Revenue in Global (2017-2022)
 - 7.30.5 Beijing Jialin Pharmaceutical Key News

8 GLOBAL ANTIHYPERURICEMIC AGENTS PRODUCTION CAPACITY, ANALYSIS

- 8.1 Global Antihyperuricemic Agents Production Capacity, 2017-2028
- 8.2 Antihyperuricemic Agents Production Capacity of Key Manufacturers in Global Market
- 8.3 Global Antihyperuricemic Agents Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

- 9.1 Market Opportunities & Trends
- 9.2 Market Drivers
- 9.3 Market Restraints

10 ANTIHYPERURICEMIC AGENTS SUPPLY CHAIN ANALYSIS

- 10.1 Antihyperuricemic Agents Industry Value Chain
- 10.2 Antihyperuricemic Agents Upstream Market
- 10.3 Antihyperuricemic Agents Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Antihyperuricemic Agents Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Antihyperuricemic Agents in Global Market

Table 2. Top Antihyperuricemic Agents Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Antihyperuricemic Agents Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Antihyperuricemic Agents Revenue Share by Companies, 2017-2022

Table 5. Global Antihyperuricemic Agents Sales by Companies, (K Units), 2017-2022

Table 6. Global Antihyperuricemic Agents Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Antihyperuricemic Agents Price (2017-2022) & (US\$/Unit)

Table 8. Global Manufacturers Antihyperuricemic Agents Product Type

Table 9. List of Global Tier 1 Antihyperuricemic Agents Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Antihyperuricemic Agents Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Antihyperuricemic Agents Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Antihyperuricemic Agents Sales (K Units), 2017-2022

Table 15. By Type - Global Antihyperuricemic Agents Sales (K Units), 2023-2028

Table 16. By Distribution Channel – Global Antihyperuricemic Agents Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Distribution Channel - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2017-2022

Table 18. By Distribution Channel - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2023-2028

Table 19. By Distribution Channel - Global Antihyperuricemic Agents Sales (K Units), 2017-2022

Table 20. By Distribution Channel - Global Antihyperuricemic Agents Sales (K Units), 2023-2028

Table 21. By Region – Global Antihyperuricemic Agents Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Antihyperuricemic Agents Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Antihyperuricemic Agents Sales (K Units), 2017-2022

Table 25. By Region - Global Antihyperuricemic Agents Sales (K Units), 2023-2028

Table 26. By Country - North America Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Antihyperuricemic Agents Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Antihyperuricemic Agents Sales, (K Units), 2017-2022

Table 29. By Country - North America Antihyperuricemic Agents Sales, (K Units), 2023-2028

Table 30. By Country - Europe Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Antihyperuricemic Agents Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Antihyperuricemic Agents Sales, (K Units), 2017-2022

Table 33. By Country - Europe Antihyperuricemic Agents Sales, (K Units), 2023-2028

Table 34. By Region - Asia Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Antihyperuricemic Agents Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Antihyperuricemic Agents Sales, (K Units), 2017-2022

Table 37. By Region - Asia Antihyperuricemic Agents Sales, (K Units), 2023-2028

Table 38. By Country - South America Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Antihyperuricemic Agents Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Antihyperuricemic Agents Sales, (K Units), 2017-2022

Table 41. By Country - South America Antihyperuricemic Agents Sales, (K Units), 2023-2028

Table 42. By Country - Middle East & Africa Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Antihyperuricemic Agents Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Antihyperuricemic Agents Sales, (K Units), 2017-2022

Table 45. By Country - Middle East & Africa Antihyperuricemic Agents Sales, (K Units), 2023-2028

Table 46. Takeda Pharmaceuticals Corporate Summary

Table 47. Takeda Pharmaceuticals Antihyperuricemic Agents Product Offerings

Table 48. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 49. Hikma Corporate Summary

Table 50. Hikma Antihyperuricemic Agents Product Offerings

Table 51. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 52. Wockhardt Corporate Summary

Table 53. Wockhardt Antihyperuricemic Agents Product Offerings

Table 54. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 55. West Ward Pharmaceuticals Corporate Summary

Table 56. West Ward Pharmaceuticals Antihyperuricemic Agents Product Offerings

Table 57. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 58. Rhea Pharmaceutical Corporate Summary

Table 59. Rhea Pharmaceutical Antihyperuricemic Agents Product Offerings

Table 60. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 61. Medinova Corporate Summary

Table 62. Medinova Antihyperuricemic Agents Product Offerings

Table 63. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 64. Odan Laboratories Corporate Summary

Table 65. Odan Laboratories Antihyperuricemic Agents Product Offerings

Table 66. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 67. TEIJIN Corporate Summary

Table 68. TEIJIN Antihyperuricemic Agents Product Offerings

Table 69. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 70. Casper Pharma Corporate Summary

Table 71. Casper Pharma Antihyperuricemic Agents Product Offerings

Table 72. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 73. Dr. Reddys Laboratories Corporate Summary

Table 74. Dr. Reddys Laboratories Antihyperuricemic Agents Product Offerings

Table 75. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 76. Teva Corporate Summary

Table 77. Teva Antihyperuricemic Agents Product Offerings

Table 78. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and

Average Price (US\$/Unit) (2017-2022)

Table 79. Zydus Pharmaceuticals Corporate Summary

Table 80. Zydus Pharmaceuticals Antihyperuricemic Agents Product Offerings

Table 81. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 82. Mylan Corporate Summary

Table 83. Mylan Antihyperuricemic Agents Product Offerings

Table 84. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 85. Sun Pharmaceutical Corporate Summary

Table 86. Sun Pharmaceutical Antihyperuricemic Agents Product Offerings

Table 87. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 88. APOTEX Corporate Summary

Table 89. APOTEX Antihyperuricemic Agents Product Offerings

Table 90. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 91. NorthStar Healthcare Corporate Summary

Table 92. NorthStar Healthcare Antihyperuricemic Agents Product Offerings

Table 93. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 94. Ipca Laboratories Corporate Summary

Table 95. Ipca Laboratories Antihyperuricemic Agents Product Offerings

Table 96. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 97. Accord Healthcare Corporate Summary

Table 98. Accord Healthcare Antihyperuricemic Agents Product Offerings

Table 99. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 100. Gentec Pharmaceutical Group Corporate Summary

Table 101. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Offerings

Table 102. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 103. Indoco Remedies Corporate Summary

Table 104. Indoco Remedies Antihyperuricemic Agents Product Offerings

Table 105. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 106. Lupin Corporate Summary

Table 107. Lupin Antihyperuricemic Agents Product Offerings

Table 108. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 109. Waterstone Pharmaceuticals Corporate Summary

Table 110. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Offerings

Table 111. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 112. ALP Pharm Corporate Summary

Table 113. ALP Pharm Antihyperuricemic Agents Product Offerings

Table 114. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 115. Jiangsu Hengrui Medicine Corporate Summary

Table 116. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Offerings

Table 117. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 118. Jiangsu Wanbang Biopharmaceuticals Corporate Summary

Table 119. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Offerings

Table 120. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 121. Hangzhou Zhuyangxin Pharmaceutical Corporate Summary

Table 122. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Offerings

Table 123. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 124. YiChang HEC ChangJiang Pharmaceutical Corporate Summary

Table 125. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Offerings

Table 126. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 127. KPC Pharmaceuticals Corporate Summary

Table 128. KPC Pharmaceuticals Antihyperuricemic Agents Product Offerings

Table 129. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 130. Tonghua Limin Corporate Summary

Table 131. Tonghua Limin Antihyperuricemic Agents Product Offerings

Table 132. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 133. Beijing Jialin Pharmaceutical Corporate Summary

Table 134. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Offerings

Table 135. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 136. Antihyperuricemic Agents Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)

Table 137. Global Antihyperuricemic Agents Capacity Market Share of Key Manufacturers, 2020-2022

Table 138. Global Antihyperuricemic Agents Production by Region, 2017-2022 (K Units)

Table 139. Global Antihyperuricemic Agents Production by Region, 2023-2028 (K Units)

Table 140. Antihyperuricemic Agents Market Opportunities & Trends in Global Market

Table 141. Antihyperuricemic Agents Market Drivers in Global Market

Table 142. Antihyperuricemic Agents Market Restraints in Global Market

Table 143. Antihyperuricemic Agents Raw Materials

Table 144. Antihyperuricemic Agents Raw Materials Suppliers in Global Market

Table 145. Typical Antihyperuricemic Agents Downstream

Table 146. Antihyperuricemic Agents Downstream Clients in Global Market

Table 147. Antihyperuricemic Agents Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

- Figure 1. Antihyperuricemic Agents Segment by Type
- Figure 2. Antihyperuricemic Agents Segment by Distribution Channel
- Figure 3. Global Antihyperuricemic Agents Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Antihyperuricemic Agents Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Antihyperuricemic Agents Revenue, 2017-2028 (US\$, Mn)
- Figure 7. Antihyperuricemic Agents Sales in Global Market: 2017-2028 (K Units)
- Figure 8. The Top 3 and 5 Players Market Share by Antihyperuricemic Agents Revenue in 2021
- Figure 9. By Type - Global Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 10. By Type - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 11. By Type - Global Antihyperuricemic Agents Price (US\$/Unit), 2017-2028
- Figure 12. By Distribution Channel - Global Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 13. By Distribution Channel - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 14. By Distribution Channel - Global Antihyperuricemic Agents Price (US\$/Unit), 2017-2028
- Figure 15. By Region - Global Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 16. By Region - Global Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 17. By Country - North America Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 18. By Country - North America Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 19. US Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 20. Canada Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 21. Mexico Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 22. By Country - Europe Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 23. By Country - Europe Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 24. Germany Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028

- Figure 25. France Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 26. U.K. Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 27. Italy Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 28. Russia Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 29. Nordic Countries Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 30. Benelux Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 31. By Region - Asia Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 32. By Region - Asia Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 33. China Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 34. Japan Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 35. South Korea Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 36. Southeast Asia Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 37. India Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 38. By Country - South America Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 39. By Country - South America Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 40. Brazil Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 41. Argentina Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 42. By Country - Middle East & Africa Antihyperuricemic Agents Revenue Market Share, 2017-2028
- Figure 43. By Country - Middle East & Africa Antihyperuricemic Agents Sales Market Share, 2017-2028
- Figure 44. Turkey Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 45. Israel Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 46. Saudi Arabia Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 47. UAE Antihyperuricemic Agents Revenue, (US\$, Mn), 2017-2028
- Figure 48. Global Antihyperuricemic Agents Production Capacity (K Units), 2017-2028
- Figure 49. The Percentage of Production Antihyperuricemic Agents by Region, 2021 VS 2028
- Figure 50. Antihyperuricemic Agents Industry Value Chain
- Figure 51. Marketing Channels

I would like to order

Product name: Antihyperuricemic Agents Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/AF2447566069EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF2447566069EN.html>